incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN
- H. Ford, A. Marshall, J. Bridgewater, T. Janowitz, F. Coxon, J Wadsley
- Int J Cancer
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.